Rorsman I, et al. - This non-randomized clinical trial was conducted to discover any potential natalizumab-related cognitive effects on multiple sclerosis (MS) patients performing below normal limits on neuropsychological testing. Following 12-months of natalizumab treatment, the outcomes indicated improvement in information processing speed. The results were described as a reflection of anti-inflammatory properties of natalizumab rather than retest- or long-term restorative effects.